Affimed Announces Positive Results Demonstrating Safety And Efficacy Of Acimtamig And Allonk® Combination In Relapsed/Refractory Classical Hodgkin Lymphoma (R/R Chl) Patients

(MENAFN - EIN Presswire) The combination of acimtamig with AlloNK– demonstrated an overall response rate of 86% and complete response of 55% in 22 heavily pretreated patients with R/R cHL, ...

By: menafn